Daclizumab Method of Action Surprises Researchers:
"A study on how daclizumab (Zenapax) might work in people with MS found unexpected results.
Researchers believed the drug prevents interaction between T-cells and the growth factor. But the new study showed the drug doesn't suppress T-cell activity. Instead, it increases activity of another component of the immune system called regulatory natural killer cells, which attack cancers and viruses. This story reveals a very important research development that could shed light on the critical question of how and why multiple sclerosis develops (or at least one version of it), and more importantly, how to effectively treat it....."